INFOGRAPHIC OF THE WEEK
In a recent market outlook analysis by Genetic Engineering & Biotechnology News, the APAC global cell and gene therapy space has been predicted to emerge as a major market. This is due to the high presence of chronic diseases in countries such as China and Japan. With the increased R&D funding, strategic acquisitions and investments, favourable regulatory developments, new product launches and approvals amongst other key growth drivers in the region, the APAC cell & gene therapy market indeed looks promising.
The above infographic pulls together 20 of the top 62 cell and gene therapy companies. It is segmented by region – namely, Singapore, Taiwan, Korea and Japan. These companies have grown over the past few year in terms of innovative product pipelines, upcoming facilities and a number of partnerships and acquisitions.
Daewoong Pharmaceutical recently announced that the Indonesian health regulators approved the phase 1 clinical trial of its DWP710, a Covid-19 treatment using mesenchymal stem cells. Similarly, Tessa Therapeutics‘ TT11 received the Food and Drug Administration (FDA) regenerative medicine advanced therapy (RMAT) designation. It is the first CAR-T therapy to have done so and is on track to become the leading cell-based therapy in Hodgkin’s lymphoma (HL). These are just some of the many recent accomplishments of cell & gene therapy companies in the APAC region. It goes without a doubt that the region is booming and there is much to look out for.
Would you like to keep yourself updated on the latest and most exclusive insights on all 62 companies? IMAPAC has compiled the APAC Cell & Gene Therapy Facilities 2020 market research report. In addition to the facility capacity and design, the report contains a thorough analysis of the products developed, technologies and equipment used, partnership and expansion plans, completed and upcoming projects and more. Key geographies analysed include China, Japan, Korea, Taiwan, SEA, India and Australia.
Send us a request for the sample insights now: Click Here!